BOSTON--(BUSINESS WIRE)--Elucid, a pioneering medical technology company providing physicians with imaging analysis software based on ground truth histology to support treatment of cardiovascular disease, today announced it has moved its headquarters to 399 Boylston Street in the heart of Boston’s Back Bay neighborhood. The move into the modern space comes as Elucid grows and prepares for commercialization of its flagship plaque analysis software.
Elucid’s move into the new headquarters follows an $80 million Series C fundraise in Q4 2023, led by Elevage Medical Technologies, which was intended to help further commercialization and expansion plans. As part of its ramp up for commercial launch, which includes hiring additional employees, Elucid sought out space that would provide room to grow, encourage collaboration and prioritize employee wellness.
The new office is centrally located just steps from Boston Public Garden and in close proximity to multiple public transit stops. Spanning more than 16,000 square feet, the Boylston Street headquarters is filled with light and offers a variety of spaces for collaborative work, and for social gatherings. In addition, there is a gym area, locker room and bike storage on premise to encourage fitness.
"This new office space feels like a perfect fit for the Elucid team,” said Amy Kruglak, vice president of People, Elucid. “This new environment will foster stronger team connections and enhance our collaborative efforts, bringing our hybrid workforce together more effectively to develop and deliver meaningful products that improve patient care. It also provides the necessary seating and infrastructure to support our three-year strategic plan."
Cardiovascular disease is the most common cause of death and disability globally, largely driven by myocardial infarction and ischemic stroke caused by atherosclerosis (plaque build-up in the arteries). Elucid offers the first histology-validated FDA-cleared software to non-invasively quantify and characterize non-calcified plaque and its components such as lipid-rich necrotic core (LRNC), giving potential insights into high-risk plaques, key drivers of risk of heart attack and stroke. The company is also pursuing an indication for non-invasive measurement of fractional flow reserve (FFRCT), uniquely derived from its PlaqueIQ technology, to measure coronary blockages and the extent of ischemia.
About Elucid
Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to help physicians better understand the root cause of cardiovascular disease. PlaqueIQ powers the company’s analysis software, the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of coronary plaques, as indicated by renowned pathologists. Elucid is also pursuing an indication for FFRCT, derived from its PlaqueIQ technology, to help identify coronary blockages and the extent of ischemia non-invasively. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. For more information, visit elucid.com.
